Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
Go back to Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency| (NASDAQ: PRME) | Delayed: 3.47 +0.26 (8.10%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.21 | 52 Week High | $21.72 | |||
| Open | $3.56 | 52 Week Low | $18.36 | |||
| Day High | $3.72 | P/E | N/A | |||
| Day Low | $3.26 | EPS | $0.00 | |||
| Volume | 8,851,867 | |||||



